← Home
🚀 Sign up Free for Public Company Valuation & Insights!
Sign up for free to get access to the best public company valuation and insights. Get started today and unlock the potential of your investments!
Sign up free Video Highlights
Ono Pharmaceutical
-65.38%
Pharma / Pharmaceuticals, Healthcare
At a Glance | Core Facts | Company Due Diligence: | Industry Due Diligence: | Competitors | Stock Swings | News | Income | Balance | Cash Flow | Growth | Enterprise | Ratios | Metrics | Dividends | Risks | SWOT | Porter's Five Forces | PEST | Score Positive | Clusters | Reports | WebOverview
Ono Pharmaceutical Co., Ltd. is a Japanese-based pharmaceutical company that was founded in 1717. The company develops, manufactures, and sells prescription medicines and over-the-counter products for a wide range of medical conditions. Ono Pharmaceutical is headquartered in Osaka, Japan and has operations in Asia, Europe, and the United States.
The company focuses on research and development in the fields of oncology, immunology, and neurology. Its products include treatments for cancer, immune disorders, infectious diseases, and other areas of unmet medical need.
Ono Pharmaceutical is committed to ethical business practices and responsible corporate citizenship. The company has implemented various initiatives to reduce its environmental impact and contribute to the well-being of communities it operates in.
Ono Pharmaceutical has collaborations and partnerships with other pharmaceutical companies, research institutions, and universities to enhance its research capabilities and bring innovative medicines to patients.
Overall, Ono Pharmaceutical is dedicated to improving the health and quality of life of individuals worldwide through the development of innovative and effective medications.
The company focuses on research and development in the fields of oncology, immunology, and neurology. Its products include treatments for cancer, immune disorders, infectious diseases, and other areas of unmet medical need.
Ono Pharmaceutical is committed to ethical business practices and responsible corporate citizenship. The company has implemented various initiatives to reduce its environmental impact and contribute to the well-being of communities it operates in.
Ono Pharmaceutical has collaborations and partnerships with other pharmaceutical companies, research institutions, and universities to enhance its research capabilities and bring innovative medicines to patients.
Overall, Ono Pharmaceutical is dedicated to improving the health and quality of life of individuals worldwide through the development of innovative and effective medications.
What is special about the company?
1. Focused on Research and Development: Ono Pharmaceutical has a strong focus on research and development, investing a significant portion of its revenue into the development of new drugs. This has allowed the company to introduce innovative and effective treatments for various diseases.
2. Strong Pipeline of Drugs: Ono Pharmaceutical has a robust pipeline of drugs, with several potential blockbuster drugs in development. This ensures a continuous source of revenue growth in the future.
3. Global Presence: The company has a global presence, with operations in Japan, the United States, and Europe. This allows it to tap into different markets and reach a wider patient population.
4. Strategic Partnerships: Ono has formed strategic partnerships with other pharmaceutical companies and biotech startups to develop new drugs and technologies. This collaboration helps the company access cutting-edge research and expand its product portfolio.
5. Commitment to Innovation: Ono Pharmaceutical has a strong commitment to innovation and is constantly investing in new technologies and approaches to boost drug development and improve patient outcomes.
6. Focus on Rare Diseases: The company has a strong focus on rare diseases, where there is a significant unmet medical need. This commitment has led to the successful development of several drugs for rare diseases.
7. Social Responsibility: Ono Pharmaceutical has a strong emphasis on social responsibility and is committed to providing affordable and accessible medicines to patients in need.
8. Strong Financial Performance: The company has consistently achieved strong financial performance, with steady revenue and profit growth. This stability and financial strength give them the resources to invest in new drug development.
9. Employee-Friendly Policies: Ono has been recognized as one of the best companies to work for in Japan. It has a positive work culture and employee-friendly policies, which have helped attract and retain top talent.
10. Commitment to Sustainability: Ono is committed to sustainable development and has set targets for reducing its environmental impact. The company also supports various social initiatives and is working towards building a more sustainable future.
2. Strong Pipeline of Drugs: Ono Pharmaceutical has a robust pipeline of drugs, with several potential blockbuster drugs in development. This ensures a continuous source of revenue growth in the future.
3. Global Presence: The company has a global presence, with operations in Japan, the United States, and Europe. This allows it to tap into different markets and reach a wider patient population.
4. Strategic Partnerships: Ono has formed strategic partnerships with other pharmaceutical companies and biotech startups to develop new drugs and technologies. This collaboration helps the company access cutting-edge research and expand its product portfolio.
5. Commitment to Innovation: Ono Pharmaceutical has a strong commitment to innovation and is constantly investing in new technologies and approaches to boost drug development and improve patient outcomes.
6. Focus on Rare Diseases: The company has a strong focus on rare diseases, where there is a significant unmet medical need. This commitment has led to the successful development of several drugs for rare diseases.
7. Social Responsibility: Ono Pharmaceutical has a strong emphasis on social responsibility and is committed to providing affordable and accessible medicines to patients in need.
8. Strong Financial Performance: The company has consistently achieved strong financial performance, with steady revenue and profit growth. This stability and financial strength give them the resources to invest in new drug development.
9. Employee-Friendly Policies: Ono has been recognized as one of the best companies to work for in Japan. It has a positive work culture and employee-friendly policies, which have helped attract and retain top talent.
10. Commitment to Sustainability: Ono is committed to sustainable development and has set targets for reducing its environmental impact. The company also supports various social initiatives and is working towards building a more sustainable future.
What the company's business model?
The Ono Pharmaceutical Company is a pharmaceutical company that focuses on the research, development, production, and sale of pharmaceutical products. Their business model is based on providing innovative and effective medical solutions for various diseases and medical conditions.
They collaborate with research institutes, universities, and other pharmaceutical companies to develop new drugs and treatments. Ono Pharmaceutical also has a strong focus on investing in cutting-edge technologies and continuously improving their existing products.
The company's main source of revenue comes from the sales of their pharmaceutical products, both in Japan and internationally. They have a diverse portfolio of products that cover various therapeutic areas, such as oncology, immunology, neurological disorders, and infectious diseases.
Ono Pharmaceutical also uses a licensing business model to expand their product portfolio by partnering with other companies to develop and commercialize their products in different markets. They also offer contract manufacturing services to other pharmaceutical companies, generating additional revenue.
In addition to their commercial activities, Ono Pharmaceutical also invests in corporate social responsibility initiatives to contribute to the well-being of society. This includes supporting healthcare-related projects and initiatives in developing countries.
Overall, the company's business model focuses on continuous innovation, strategic collaborations, and ethical business practices to provide high-quality and effective medical solutions for patients worldwide.
They collaborate with research institutes, universities, and other pharmaceutical companies to develop new drugs and treatments. Ono Pharmaceutical also has a strong focus on investing in cutting-edge technologies and continuously improving their existing products.
The company's main source of revenue comes from the sales of their pharmaceutical products, both in Japan and internationally. They have a diverse portfolio of products that cover various therapeutic areas, such as oncology, immunology, neurological disorders, and infectious diseases.
Ono Pharmaceutical also uses a licensing business model to expand their product portfolio by partnering with other companies to develop and commercialize their products in different markets. They also offer contract manufacturing services to other pharmaceutical companies, generating additional revenue.
In addition to their commercial activities, Ono Pharmaceutical also invests in corporate social responsibility initiatives to contribute to the well-being of society. This includes supporting healthcare-related projects and initiatives in developing countries.
Overall, the company's business model focuses on continuous innovation, strategic collaborations, and ethical business practices to provide high-quality and effective medical solutions for patients worldwide.
Interesting facts about the company
makes tablets
1. Founded in 1717: The Ono Pharmaceutical company was founded in 1717 as a traditional herbal medicine store in Osaka, Japan. It was called Ono Genzaemon Shoten.
2. Entered the pharmaceutical industry in 1899: In 1899, the company started importing pharmaceutical raw materials from abroad and entered the pharmaceutical industry.
3. First Japanese company to manufacture penicillin: In 1946, Ono Pharmaceutical became the first Japanese company to manufacture penicillin.
4. Developed Japan’s first tranquilizer: In 1955, the company developed Japan’s first tranquilizer called Elenium Elixir.
5. Launch of first drug for hypertension: In 1967, Ono Pharmaceutical launched the first antihypertensive drug in Japan called Capoten.
6. Introduction of the first Japanese-made anticancer drug: In 1974, the company introduced the first Japanese-made anticancer drug called Bosch Pharma, which is still widely used today.
7. Collaboration with Lilly: In 1982, Ono Pharmaceutical entered into a collaboration with Eli Lilly and Company to develop and market pharmaceutical products in Japan.
8. Partnership with Bristol-Myers Squibb: In 2006, Ono Pharmaceutical signed an agreement with Bristol-Myers Squibb for the co-development and co-commercialization of drugs for cancer, central nervous system disorders, and autoimmune diseases.
9. Global expansion: Ono Pharmaceutical has expanded its business to over 84 countries and regions around the world, with a focus on Asia, North America, and Europe.
10. Sustainable development: The company is committed to sustainable development and has set goals to reduce its environmental impact, promote diversity and inclusion, and contribute to society through various initiatives.
See Company Due Diligence:
1. Founded in 1717: The Ono Pharmaceutical company was founded in 1717 as a traditional herbal medicine store in Osaka, Japan. It was called Ono Genzaemon Shoten.
2. Entered the pharmaceutical industry in 1899: In 1899, the company started importing pharmaceutical raw materials from abroad and entered the pharmaceutical industry.
3. First Japanese company to manufacture penicillin: In 1946, Ono Pharmaceutical became the first Japanese company to manufacture penicillin.
4. Developed Japan’s first tranquilizer: In 1955, the company developed Japan’s first tranquilizer called Elenium Elixir.
5. Launch of first drug for hypertension: In 1967, Ono Pharmaceutical launched the first antihypertensive drug in Japan called Capoten.
6. Introduction of the first Japanese-made anticancer drug: In 1974, the company introduced the first Japanese-made anticancer drug called Bosch Pharma, which is still widely used today.
7. Collaboration with Lilly: In 1982, Ono Pharmaceutical entered into a collaboration with Eli Lilly and Company to develop and market pharmaceutical products in Japan.
8. Partnership with Bristol-Myers Squibb: In 2006, Ono Pharmaceutical signed an agreement with Bristol-Myers Squibb for the co-development and co-commercialization of drugs for cancer, central nervous system disorders, and autoimmune diseases.
9. Global expansion: Ono Pharmaceutical has expanded its business to over 84 countries and regions around the world, with a focus on Asia, North America, and Europe.
10. Sustainable development: The company is committed to sustainable development and has set goals to reduce its environmental impact, promote diversity and inclusion, and contribute to society through various initiatives.
See Company Due Diligence:
Wait! There's more — sign up for free or log in